{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:43:30Z","timestamp":1793857410456,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."},{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01705-2","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:14:24Z","timestamp":1749186864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies"],"prefix":"10.1186","volume":"18","author":[{"given":"Quchang","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunPeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuizhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna V.","family":"Ulahannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Chartash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omobolaji O.","family":"Akala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"1705_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 4.2023 https:\/\/www.nccn.org\/. Accessed February 15, 2023."},{"key":"1705_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-021-06337-x","volume":"190","author":"A Hanna","year":"2021","unstructured":"Hanna A, Balko JM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat. 2021;190:5\u201317.","journal-title":"Breast Cancer Res Treat"},{"key":"1705_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1078-0432.CCR-21-2947","volume":"28","author":"MR Lloyd","year":"2022","unstructured":"Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of resistance to CDK4\/6 blockade in advanced hormone receptor-positive, HER2-negative breast cancer and emerging therapeutic opportunities. Clin Cancer Res. 2022;28:821\u201330.","journal-title":"Clin Cancer Res"},{"key":"1705_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:84\u2013105.","journal-title":"Genes Cancer"},{"key":"1705_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59:701\u201310.","journal-title":"J Histochem Cytochem"},{"key":"1705_CR7","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989\u20139006.","journal-title":"Oncotarget"},{"key":"1705_CR8","doi-asserted-by":"publisher","first-page":"28725","DOI":"10.18632\/oncotarget.15647","volume":"8","author":"K Inamura","year":"2017","unstructured":"Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Subat S, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725\u201335.","journal-title":"Oncotarget"},{"key":"1705_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"1705_CR10","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40:3365\u201376.","journal-title":"J Clin Oncol"},{"key":"1705_CR11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423\u201333.","journal-title":"Lancet"},{"key":"1705_CR12","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","volume":"12","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front Oncol. 2022;12:951589.","journal-title":"Front Oncol"},{"key":"1705_CR13","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008;27:2420\u201339.","journal-title":"Stat Med"},{"key":"1705_CR14","doi-asserted-by":"crossref","unstructured":"Xu B, Yin Y, Fan Y, Ouyang Q, Song L, Wang X, et al. Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study. J Clin Oncol. 2024;42:104.","DOI":"10.1200\/JCO.2024.42.16_suppl.104"},{"key":"1705_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"1705_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356.","journal-title":"Ann Oncol"},{"key":"1705_CR17","doi-asserted-by":"crossref","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42:2281\u201394.","DOI":"10.1200\/JCO.23.01909"},{"key":"1705_CR18","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O\u2019Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Ann Oncol. 2020;31:1709\u201318.","journal-title":"Ann Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01705-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:14:28Z","timestamp":1749186868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01705-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01705-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and its amendments were approved by an institutional review board or institutional ethics committee at each study site, including the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB 1 IRB00000121) and the Medical Ethics Committee of Shanghai East Hospital Affiliated to Tongii University School of Medicine (2020 [015]).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Quchang Ouyang: None declared.\u00a0Jordi Rodon: Dr Rodon reports non-financial support and reasonable reimbursement for travel from European Society for Medical Oncology, American Society of Medical Oncology, National Taiwan University Cancer Center, 280-Biotech, Dava Oncology, STOP Cancer; receiving consulting and travel fees from Ellipses Pharma, IONCTURA, Sardona, Mekanistic, Amgen, Merus, MonteRosa, Aadi, and Bridgebio (including serving on the scientific advisory board); Consulting fees from Vall d'Hebron Institute of Oncology, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC, Guidepoint, and Axiom; receiving research funding from Blueprint Medicines, MSD, Hummingbird, AstraZenneca, 280 Bio, Vall d'Hebron Institute of Oncology\/Cancer Core Europe; and serving as investigator in clinical trials with Cancer Core Europe, Symphogen, BioAlta, Pfizer, Kelun-Biotech, GlaxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bicycle Therapeutics, Merus, AadiBioscience, ForeBio, Loxo Oncology, Hutchinson MediPharma, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics, MonteRosa, Kinnate, Yingli, Debio, BioTheryX, Storm Therapeutics, Beigene, MapKure, Relay, Novartis, FusionPharma, C4 Therapeutics, Scorpion Therapeutics, Incyte, Fog Pharmaceuticals, Tyra, Nuvectis Pharma, Hotspot Pharma, Adcentrix, Vividion, AstraZenneca, Alnylam, Immuneering Corp, Alterome, Exelixis.Yan Liang: None declared.Xinhong Wu: None declared.Qun Li: None declared.Lihua Song: None declared.Min Yan: None declared.Zhongsheng Tong: None declared.YunPeng Liu: None declared.Zev A. Wainberg: None declared.Ying Wang: None declared.Cuizhi Geng: None declared.Susanna V.\u00a0Ulahannan: Research funding to institution: AbbVie Inc, Adlai Nortye, ArQule Inc, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Ciclomed LLC, Erasca, Evelo Biosciences Inc., Exelexis, G1 Therapeutics Inc, GlaxoSmithKline GSK, IGM biosciences, Incyte, Isofol, Klus Pharma Inc., Macrogenics, MSD, Mersana Therapeutics, OncoMed Pharmaceuticals Inc., Pfizer, Regeneron Inc., Revolution Medicines Inc., Synermore Biologics Co, Takeda, Tarveda Therapeutics, Tesaro, Tempest, and Vigeo Therapeutics Inc.; Advisory Board for Eisai, AstraZeneca, and IgM biosciences.Guohua Yu: None declared.Manish R.\u00a0Sharma: Research funding to institution: Arcus Bioscience, AbbVie, Adcentrx Therapeutics, Alkermes, ALX Oncology, Artios Pharma, Astellas, Aulos Bioscience, BioNTech, Black Diamond Therepeutics, Boundless Bio, Bolt Biotherapeutics, Boehringer Ingelheim, Bright Peak Therapeutics, Bristol Myers Squibb, Biontech, Celgene, Chugai Pharmaceutical, Circle Pharma, Cullinan, Compugen, Constellation Pharmaceuticals, Debiopharm, Deciphera Pharmaceuticals, eFFECTOR, Elevation Oncology, Exelixis, GenMab, Gilead Sciences, GlaxoSmithKline, Iambic Therapeutics, IgM Biosciences, Ikena, Inhibrx, Incyte, Janssen, KLUS Pharma, Lilly, LOXO Oncology, Macrogenics, MSD, Mirati, NGM Biosciences, Onconova, Opna Bio, Palleon, Pfizer, Pliant Therapeutics, ProfoundBio, PureTech, Qualigen, Regeneron Pharmaceuticals, Repare Therapeutics, Revolution Medicines, Roche, Sapience Therapeutics, Seagen, Shattuck Labs, Stemline Therapeutics, Symphogen, Tempest Therapeutics, Theratechnologies, Tizona Therapeutics, Volastra Therapeutics, and 23andMe Therapeutics; Consulting for Pliant Therapeutics, Enlaza Therapeutics, and Aadi Bioscience; Stock Ownership of AbbVie, Amgen, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Moderna, Regeneron, and West Pharmaceutical.Xiang Wang: None declared.Judy S.\u00a0Wang: Research funding by Kelun\/Klus and MSD, to institution only.Alexander Spira: Research funding from Abbvie, ADC Therapeutics, Alkermes, Amgen, Arch Therapeutics, ArriVent Biopharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, BluPrint Oncology, Boehringer Ingelheim, Bristol-Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gritstone Bio, Ignyta, Incyte, Janssen Oncology, LAM Therapeutics, Loxo, Macrogenics, Medikine, MedImmune, mersana, Mirati Therapeutics, Nalo Therapeutics, Novartis, Plexxikon, Regeneron, Revolution Medicines, Revolution Medicines, Roche, Rubius Therapeutics, Scorpion Therapeutics, Synthekine, and Takeda; Consulting or advisory role for Amgen, Array BioPharma, AstraZeneca\/MedImmune, AstraZeneca\/MedImmune, Black Diamond Therapeutics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo\/Astra Zeneca, Gritstone Bio, Incyte, Janssen Research & Development, Jazz Pharmaceuticals, Lilly, MSD, Mersana, Mirati Therapeutics, Novartis, Regeneron, Sanofi, and Takeda; Honoraria from Amgen, AstraZeneca\/MedImmune, Bayer, Bristol-Myers Squibb, CytomX Therapeutics, Janssen Oncology, MSD, Novartis, and Takeda; Stock and Other Ownership Interests for Lilly; and Leadership role for Next Oncology.Weihong Zhao: None declared.Rachel E.\u00a0Sanborn: Advisor for Abbvie, Amgen, AstraZeneca, Daiichi Sankyo, G1 Therapeutics, GE HealthCare, Gilead, Janssen Oncology, Johnson & Johnson, Inhibrx, Lilly Oncology, Regeneron, and Sanofi Aventis; Honoraria for educational presentations from Illumina, OncLive, and PRIME Education; Steering Committee for AstraZeneca, BeiGene, GlaxoSmithKline, Janssen Oncology, and Johnson & Johnson; Honoraria from CurioScience and IDEOlogy.Ying Cheng: None declared.Xian Wang: None declared.Gesha Liu: None declared.Yaling Li: None declared.Junyou Ge: None declared.Elliot Chartash: employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA.Omobolaji O. Akala: employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA.Yongmei Yin: None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}